Not very NICE (via Atomic Spin)

Last week, the drugs regulatory body and tabloid scapegoat NICE decided not to allow funding for the bowel cancer drug Avastin on the grounds that spending £21,000 per patient to extend their life by, on average, six weeks was not an effective use of NHS funds (Ben Goldacre has a brilliant column on the media scrum surrounding this decision). It’s a difficult choice, and it must be devastating news for families of bowel cancer sufferers, but on b … Read More

via Atomic Spin